EISAI CO LTD (EII DU) stock market data APIs
€25.5623
0.21(0.8%)
as of September 10, 2026
Try our APIs with
free plan!
EISAI CO LTD Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EII.DU.
Prev. Close
25.5623
Open
25.768
High
25.768
Low
25.2375
52 wk Range
19.485-29.0367
Market Cap
15 022 M
EPS
46.4
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EISAI CO LTD data using free add-ons & libraries
Get EISAI CO LTD Fundamental Data
EISAI CO LTD Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-05-14
- EPS/Forecast: 35.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EISAI CO LTD News
New
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The trea...
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Biogen Inc. The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease TOKYO and CAMBRIDGE, Mass., Sept. 03...
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Biogen Inc. An Important Step Forward for Access to LEQEMBI® for Eligible Patients in Canada TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: B...
Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab)
Recommendation advances equitable access discussions for eligible Canadians and highlights the urgency of timely reimbursement, as Alzheimer's disease progression does not wait MISSISSAUGA, ON and TO...
Get EISAI CO LTD fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
